Disease · MONDO_0007935

cystoid macular edema

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cystoid macular edema. Diseases, record MONDO_0007935. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007935

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cystoid macular edema; Open Targets
Open Targets ID: MONDO_0007935; Open Targets
Other names: Cystoid macular dystrophy, DCMD, autosomal dominant cystoid macular edema, autosomal dominant cystoid macular oedema, familial macular edema, familial macular oedema; Open Targets
Disease Ontology: DOID:4447; Disease Ontology
NCI Thesaurus: C34794; NCI Thesaurus
Orphanet: ORPHA:75381; Orphanet
Highest stage of its drugs: Approval, for 1 of its 16 drugs, from FDA; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FARICIMAB	CHEMBL4297750	Antibody	Approval	FDA	1	0	0	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
KETOROLAC	CHEMBL469	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE ACETATE	CHEMBL1152	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ACETAZOLAMIDE	CHEMBL20	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BROMFENAC	CHEMBL1077	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 1/2	ClinicalTrials.gov	3	3	3	Drugs and targets
MINOCYCLINE	CHEMBL1434	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
PEGAPTANIB SODIUM	CHEMBL1201421	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VEGFA	Vascular endothelial growth factor A, long form	5	Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor	Approval	https://conductscience.org/library/genes/7422	Drugs and targets
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	3	Cyclooxygenase inhibitor	Phase 2/3	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	3	Cyclooxygenase inhibitor	Phase 2/3	https://conductscience.org/library/genes/5743	Drugs and targets
ANGPT2	Angiopoietin-2	1	Angiopoietin-2 inhibitor	Approval	https://conductscience.org/library/genes/285	Drugs and targets
CA1	Carbonic anhydrase 1	1	Carbonic anhydrase I inhibitor	Phase 2	https://conductscience.org/library/genes/759	Drugs and targets
CA12	Carbonic anhydrase 12	1	Carbonic anhydrase XII inhibitor	Phase 2	https://conductscience.org/library/genes/771	Drugs and targets
CA2	Carbonic anhydrase 2	1	Carbonic anhydrase II inhibitor	Phase 2	https://conductscience.org/library/genes/760	Drugs and targets
CA4	Carbonic anhydrase 4	1	Carbonic anhydrase IV inhibitor	Phase 2	https://conductscience.org/library/genes/762	Drugs and targets
IFNGR1	Interferon gamma receptor	1	Interferon gamma receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3459	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01769352	Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)	Phase 2/3	42	2017-09-15	Post-surgical Cystoid Macular Edema (PSCME)	KETOROLAC, PREDNISOLONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00498355	Lucentis for Inflammatory Macular Edema Trial	Phase 1/2	7	2012-09-21	Uveitis, Cytoid Macular Edema	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02140164	Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa	Phase 1/2	7	2017-01-16	Retinitis Pigmentosa	MINOCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT00826618	Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema	Phase 1	6	2014-08-26	Uveitic Cystoid Macular Edema	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00790803	Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema	Not applicable	5	2013-09-26	Uveitis, Cystoid Macular Edema	PEGAPTANIB SODIUM	Its record names the disease	ClinicalTrials.gov
NCT01376362	Topical Interferon Gamma for Macular Edema Secondary to Uveitis	Phase 1/2	5	2012-10-08	Anterior Uveitis, Uveitis	INTERFERON GAMMA-1B	Its record names the disease	ClinicalTrials.gov
NCT00371111	To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema	Phase 1	40		Resistant Cystoid Macular Edema	BEVACIZUMAB, TRIAMCINOLONE	Its record names the disease	ClinicalTrials.gov
NCT03559491	Dexamethasone Intravitreal Implant in Retinal Vein Occlusion		30		Macular Edema, Cystoid	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT01284478	Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery	Phase 2	6		Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT04225611	Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema	Phase 1/2	6		Cystoid Macular Edema	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Prednisolone Acetate Every 1 Hour While Awake (Group 1) vs Prednisolone Acetate Four Times a Day (Group 2): deaths from any cause	0 of 22	0 of 20	42	NCT01769352	Trial comparisons
Prednisolone Acetate Every 1 Hour While Awake (Group 1) vs Prednisolone Acetate Four Times a Day (Group 2): serious adverse events	5 of 22	4 of 20	42	NCT01769352	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36882562	RESULT	1	PubMed
27604764	RESULT	1	PubMed
36912792	DERIVED	1	PubMed
30175123	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007935

GET https://conductscience.org/api/diseases/v1/MONDO_0007935/drugs

API reference For AI assistants